nxp800
nxp800: developed by 1 company · 1 clinical trial tracked.
nxp800 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect nxp800 to NVCT; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could nxp800 → NVCT affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Advanced Solid TumorOvarian Cancer
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Nuvectis Pharma, Inc. (NVCT) Advanced Solid Tumor | Phase 1 |
Clinical Trials (1)
A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer
Primary endpoint: Part A: Number of patients with treatment related adverse events, clinical laboratory abnormalities, dose limiting toxicities
Interventionalopen45 enrolledStarted 2021-12Completion 2025-0122 sites · United Kingdom, United StatesNuvectis Pharma, Inc.
Frequently asked questions
Who is developing nxp800?
nxp800 is being developed by Nuvectis Pharma, Inc..
How many clinical trials involve nxp800?
BioSniper tracks 1 clinical trial involving nxp800.